Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2021

View Archived Issues

Enrollment opens in phase IIa study of MK-1942 in treatment-resistant depression

Aprea begins enrollment in first-in-human study of APR-548 for TP53-mutated MDS

Prime, base editing are "finer scalpels" in dystrophy

APVO-442: a bispecific T-cell engager targeting PSMA and CD3 for treating prostate cancer

Proof of concept demonstrated with ABX-002 prodrug brain delivery of thyromimetic LL-340001

Zenshine compounds targeting E-NPP 1 have antitumor activity

Vaxart initiates enrollment in phase Ib boosting regimen trial of its norovirus vaccine

Revolo presents encouraging safety data for its peptide drug for allergic disease

Incyte discloses new CDK2/cyclin E inhibitors

BeiGene synthesizes STING modulators

BioCryst Pharmaceuticals presents complement factor D inhibitors

Cellectar Biosciences describes new phospholipid-drug conjugates for cancer

First healthy volunteers dosed in phase I/II study of HDT Bio's COVID-19 RNA vaccine in India

Fate Therapeutics patents new CARs for cancer immunotherapy

Betacellulin is a novel therapeutic target in schizophrenia

Positive topline data from GENESIS phase III study of motixafortide plus G-CSF in multiple myeloma

Kiniksa reports final data from first-in-human trial of KPL-404

New mutations in the SETX gene tied to ataxia with oculomotor apraxia type 2

Ascletis reports phase IIa data on ASC-22 for chronic hepatitis B

FDA clears IND for phase I/II study of Clarity's prostate cancer theranostic products

European Commission approves Sibnayal for distal renal tubular acidosis

Preclinical characterization of novel small molecule inhibitor of CD38, RBN-013209

SOM-3355 reduces chorea in patients with HD

Tecentriq approved in E.U. for first-line metastatic NSCLC with high PD-L1 expression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...